ArticlePloS one2026
C-reactive protein-triglyceride-glucose index versus triglyceride-glucose index in predicting cardiovascular metabolic multimorbidity risk: A cohort study.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiovascular Metabolic Multimorbidity (CMM), a leading global cause of mortality, lacks evidence on the predictive utility of the novel C-reactive protein-triglyceride-glucose index (CTI), which integrates insulin resistance and inflammation. This study compared CTI with the established Triglyceride-Glucose (TyG) index in predicting CMM risk.
methodsA cohort of 8,487 adults aged ≥45 from the CHARLS database (2011-2020) was analyzed. Over nine years, CMM events were tracked. Cox regression, restricted cubic spline (RCS), and ROC curve analyses assessed associations between TyG, CTI, and CMM risk. Subgroup analyses evaluated population-specific variations.
resultsAmong participants, 1,030 (12.14%) developed CMM. Unadjusted Cox models showed TyG (HR = 1.89, 95%CI 1.73-2.07, P < 0.001) and CTI (HR = 1.83, 95%CI 1.70-1.97, P < 0.001) predicted CMM; adjusted models confirmed persistence. A dose-response association was observed for both CTI and TyG with CMM risk. In fully adjusted models, the overall dose-response trend remained similar. ROC analysis favored CTI (higher AUC). Subgroup analyses indicated TyG's association varied by sex, smoking, and hypertension (P < 0.05), while CTI's association differed by age, sex, and hypertension (P < 0.05).
conclusionsElevated CTI independently correlates with increased CMM risk, demonstrating superior predictive accuracy over TyG. Its linear association highlights potential clinical utility for early CMM risk stratification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.